


## PHARMACEUTICAL 2022



## Immuneering Corp Rank 107 of 475







RealRate

PHARMACEUTICAL 2022



Immuneering Corp Rank 107 of 475

The relative strengths and weaknesses of Immuneering Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immuneering Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 157% points. The greatest weakness of Immuneering Corp is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 40%, being 316% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	152,334
Cost of Goods Sold	1,153
Intangible Assets	7,141
Liabilities, Current	5,634
Liabilities, Non-Current	5,091
Other Assets	6,423
Other Compr. Net Income	-49
Other Expenses	-307
Other Liabilities	0
Other Net Income	43
Property and Equipment	807
Research and Development	26,541
Revenues	2,080
Selling, General and Administrative Expense	8,272

Output Variable	Value in 1000 USD
Assets	166,705
Liabilities	10,725
Expenses	35,659
Stockholders Equity	155,980
Net Income	-33,536
Comprehensive Net Income	-33,560
Economic Capital Ratio	40%

